Related Experiment Video
Updated: Jun 19, 2025
06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
1.4K
The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats
A T Larsen1, K E Mohamed, E A Petersen
1Anna Thorsø Larsen, Nordic Bioscience A/S, Herlev Hovedgade 207, DK-2730, Herlev, Denmark. Tel: +45 44525252.
The Journal of Prevention of Alzheimer'S Disease
|July 24, 2024
Summary
Dual amylin and calcitonin receptor agonists (DACRAs) show promise for treating cognitive dysfunction. The DACRA KBP-336 improved spatial learning and memory in diabetic rats, outperforming an amylin analog.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Insulin resistance and diabetes are linked to cognitive dysfunction.
- Anti-diabetic drugs are potential treatments for neurodegenerative disorders.
- Dual amylin and calcitonin receptor agonists (DACRAs) improve glycemic control and insulin sensitivity.
Purpose of the Study:
- To investigate the effects of DACRAs on cognitive function in a diabetic rat model.
- To compare the efficacy of a specific DACRA (KBP-336) with an amylin analog (AM1213) on cognitive performance and glycemic control.
Main Methods:
- Zucker Diabetic Fatty rats were treated with KBP-336, AM1213, or vehicle for 18 weeks.
- A late intervention group received KBP-336 starting on day 30.
- Spatial learning and memory were assessed using the Morris Water Maze.
Main Results:
- KBP-336 treatment significantly improved spatial learning compared to AM1213, vehicle, and late intervention.
- Both KBP-336 and AM1213 enhanced spatial memory over vehicle treatment.
- KBP-336 demonstrated superior glycemic control compared to AM1213.
Conclusions:
- The DACRA KBP-336 ameliorates diabetes-induced spatial learning and memory deficits in diabetic rats.
- KBP-336 exhibits superior long-term glycemic control compared to the amylin analog AM1213.
- KBP-336 is a promising therapeutic candidate for cognitive impairments due to its anti-diabetic and insulin-sensitizing effects.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
01:23Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180